Relationship between calculated carboplatin area under the curve, using the Cockcroft-Calvert formula and the Chatelut formula, and thrombocytopenia induced by intraperitoneal carboplatin in combination with intravenous cyclophosphamide

被引：1

作者：

Fujiwara K. ^{[1
]}

Yamauchi H. ^{[1
]}

Yoshida T. ^{[1
]}

Kohn I. ^{[1
]}

机构：

[1] Department of Obstetrics, Kawasaki Medical School, Kurashiki 701-0192

来源：

International Journal of Clinical Oncology | 1998年 / 3卷 / 5期

关键词：

Carboplatin; Chatelut formula; Cockcroft- Calvert formula; Cyclophosphamide; Intraperitoneal administration;

D O I：

10.1007/BF02628051

中图分类号：

学科分类号：

摘要：

Background. There is no standard formula to estimate doses for the intraperitoneal (IP) administration of carboplatin. We evaluated a combination of the Cockcroft and the Calvert (Cockcroft-Calvert) formula to determine the area under the curve (AUC) for IP carboplatin co-administered with intravenous (IV) cyclophosphamide (CPM). We also evaluated the correlation of carboplatin clearance determined by the Chatelut formula with carboplatin clearance determined by the Cockcroft-Calvert formula. Methods. We performed a retrospective study of the records of 149 treatments in 30 patients who received IP carboplatin and IV CPM for ovarian carcinoma. The glomerular filtration rate was calculated with the Cockcroft formula. Carboplatin doses were determined based on the body surface area. The Cockcroft-Calvert formula was used to calculate the AUC. The Chatelut formula was also used to calculate the clearance of carboplatin and the AUC. Results. The AUC calculated with the Cockcroft-Calvert formula was well correlated to the AUC calculated with the Chatelut formula (r2 = 0.965). During the first four courses of IP carboplatin combined with IV CPM (300-500 mg/m2), the correlation between the percent decrease in platelet count and the calculated carboplatin AUC varied among methods: Cockcroft-Calvert formula AUC: r2 = 0.460; Chatelut formula AUC: r2 = 0.431; body surface area dose: r2 = 0.204; total dose: r2 = 0.143. Conclusion. To decrease patient platelet count by 67%, the optimal target AUC following IP administration of carboplatin in combination with 300-500 mg CPM/m2 IV was calculated as 6.5, using the Cockcroft-Calvert formula, and as 7.5, using the Chatelut formula. Considerable modification of the IP carboplatin dose is required after the fourth course. A prospective study is ongoing to confirm these results.

引用

页码：304 / 310

页数：6

共 17 条

[1]

Egorin M.J., Van Echo D.A., Olman E.A., Et al., Pharmacokinetics and dosage reduction of cis-diammine (1, 1-cyclobutane-dicarboxylato) platinum in patients with impaired renal function, Cancer Res, 44, pp. 5432-5438, (1984)

[2]

Calvert A.H., Newell D.R., Gumbell L.A., Et al., Carboplatin dosage: Prospective evaluation of a simple formula based on renal function, J Clin Oncol, 7, pp. 1748-1756, (1989)

[3]

Jodrell D.I., Egorin M.I., Canetta R.M., Et al., Relationship between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer, J Chin Oncol, 10, pp. 520-528, (1992)

[4]

Childs W.J., Nicholls E.J., Horwiich A., The optimization of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ cell tumours of the testis, Ann Oncol, 3, pp. 291-296, (1992)

[5]

Horwich A., Dearnaley D.P., Jay N.G., Et al., Effectiveness of carboplatin, etoposide and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors, J Clin Oncol, 9, pp. 62-69, (1991)

[6]

Newell D.R., Eeles R.A., Gumbrell L.A., Et al., Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma, Cancer Chemother Pharmacol, 23, pp. 367-372, (1989)

[7]

Reyno L.M., Egorin M.J., Canetta R.M., Et al., Impact of CPM on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer, J Clin Oncol, 11, pp. 1156-1164, (1993)

[8]

Sorensen B.T., Stromgren A., Jakobsen P., Jakobsen A., Dosetoxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients, Cancer Chemother Pharmacol, 28, pp. 397-401, (1991)

[9]

Fujiwara K., Yamauchi H., Sawada S., Et al., The pharmacokinetics of intraperitoneal carboplatin (CBDCA) and dose-up study of intravenous cyclophosphamide in combination with intraperitoneal CBDCA for advanced ovarian cancer patients, Jpn J Cancer Chemother, 19, pp. 2373-2379, (1992)

[10]

Chantler C., Garnett E.S., Parsons V., Veall N., Glomerular filtration rate measurement in man by single injection method using <sup>51</sup>Cr-EDTA, Clin Sci, 37, pp. 169-180, (1969)

← 1 2 →